A Phase 2b Multicenter, Long-Term Extension, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis - FRONTIER 2: Efficacy and Safety of JNJ-77242113 in Moderate to Severe Plaque Psoriasis

Janssen-Cilag International NV0 个研究点目标入组 240 人2022年4月19日

概览

暂无简介。

注册库

who.int

开始日期

2022年4月19日

结束日期

待定

最后更新

去年

研究类型

Interventional clinical trial of medicinal product

性别

All

发起方

•1\. Must have completed the Week 16 visit in Protocol 77242113PSO2001\.
•2\. In the opinion of the investigator, may benefit from inclusion in this LTE study.
•3\. Must agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during the study.
•4\. Must agree to discontinue all topical therapies that could affect psoriasis or the PASI or IGA evaluation, other than nonmedicated emollient and salicylic acid shampoos, prior to first administration of study intervention.
•5\. A woman of childbearing potential must have a negative urine pregnancy test at Week 0 prior to dispensing study intervention.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 216
•F.1\.3 Elderly (\>\=65 years) yes

•1\. Was permanently discontinued from study intervention in Protocol 77242113PSO2001 for any reason.
•2\. Has received any biologic therapy or experimental therapy since completion of the originating study, 77242113PSO2001\.
•3\. Has received any phototherapy or systemic treatment, with the exception of systemic corticosteroids taken \<2 weeks in duration, that could impact the assessment of psoriasis (PASI/IGA) since completion of the originating study, 77242113PSO2001, and within 4 weeks of the first administration of study intervention.
•4\. Has received any live virus or bacterial vaccination within 12 weeks before the first administration of study intervention. For exclusions related to the bacille Calmette\-Guerin (BCG) vaccine, see Exclusion 5\.
•5\. Has received the BCG vaccine within 12 months of the first administration of study intervention.